A robotic-assisted Kasai surgical procedure results in less blood loss, faster bowel function recovery, and greater rates of clearing jaundice at three and six…
News
HEPATITIS
NewsABI-4334 shows promise in hepatitis B Phase 1b trial: Data
Oral therapy ABI-4334 shows potent antiviral activity in adults with chronic hepatitis B virus (HBV) infection, according to interim data from an ongoing Phase…
CHOLANGITIS
NewsLiver donor type may sway primary sclerosing cholangitis outcomes
Liver transplants from a living donor may mean a lower success and a higher need for a second transplant relative to those from a deceased…
CHOLESTASIS
NewsNew TJP2 mutations detected in girl with mild PFIC4
A combination of two new mutations in the TJP2 gene was identified as the cause of a mild form of progressive familial intrahepatic cholestasis type 4 (PFIC4) in…
FATTY LIVER DISEASE
NewsLoss of FBP1 protein behind MASH progression to liver cancer: Study
A molecular system controlled by a protein called FBP1 is responsible for how liver cells damaged by MASH — fully, metabolic dysfunction-associated steatohepatitis, a severe…
ALAGILLE SYNDROME
NewsScreening for skull deformities necessary in some Alagille patients
Alagille syndrome may cause problems with skull development that can put abnormal pressure on the brain, and screening babies at risk for these rare…
In 2024, Liver Disease News kept readers informed aboout liver disease research, treatments, and clinical trials. Here are the 10 most read stories, each with…
BILIARY ATRESIA
NewsAbnormal amino acid profile seen in biliary atresia infants after birth
The blood levels of four amino acids, the building blocks of proteins, are significantly elevated in infants with biliary atresia within 72 hours of…
Tobevibart and elebsiran, an experimental treatment combination that Vir Biotechnology is developing for chronic hepatitis D, has been awarded both breakthrough therapy designation…
CHOLANGITIS
NewsCommittee recommends seladelpar approval in EU for treating PBC
A branch of the European Medicines Agency (EMA) has recommended that Gilead Sciences’ oral therapy seladelpar be approved in the European Union as a…
Recent Posts
- Getting ahead of concerns about fatty liver disease in children
- Early trial results testing maralixibat for hard-to-treat itching due by year’s end
- My child with Alagille syndrome is going through a ‘picky eater’ phase
- Biliary atresia treatment AX-0810 faring well in early testing
- Clinical trial results support bepirovirsen for hepatitis B